
Tectonic Therapeutics’ Promising Progress: Interim Results Reveal Positive Impact of TX45 on Group 2 Pulmonary Hypertension in HFpEF Patients
Tectonic Therapeutics’ TX45 Shows Promise in Phase 1b Clinical Trial for Pulmonary Hypertension In a groundbreaking development, Tectonic Therapeutics, a leading biotech company, recently announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45. This long-acting, Fc-relaxin fusion protein is designed to address the unmet medical need…